Table 3.

Detectability of ¹⁸F-Fluciclovine PET/CT by PSA and testosterone levels

	No. of patients	No. of positive	Positivity rate (%)
All patients	28	7	25
Stratified by PSA
PSA ≤ 0.2 ng/mL	10	1	10
PSA > 0.2 ng/mL	18	6	33.3
			P=0.172*
Stratified by castration
CRPC
PSA ≤ 0.2 ng/mL	5	1	20
PSA > 0.2 ng/mL	4	2	50
			P=0.343*
CSPC
PSA ≤ 0.2 ng/mL	5	0	0
PSA > 0.2 ng/mL	14	4	28.6
			P=0.179*

PSA, prostate-specific antigen; CSPC, castration-sensitive prostate cancer; CRPC, castration-resistant prostate cancer.

^*Comparison across 2 strata by the Fisher’s Exact test.